ArticleIET nanobiotechnology2019
Redox/pH dual stimuli-responsive ZnO QDs-gated mesoporous silica nanoparticles as carriers in cancer therapy.
Article in IET nanobiotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 16 citations in OpenAlex.
- pH-Responsive Pesticide-Loaded Hollow Mesoporous Silica Nanoparticles with ZnO Quantum Dots as a Gatekeeper for Control of Rice Blast Disease.Materials (Basel, Switzerland) · 2024Article
- Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect.Pharmaceutics · 2021Review
- Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment.Pharmaceutics · 2021Review
- The Opportunities and Challenges of Silica Nanomaterial for Atherosclerosis.International journal of nanomedicine · 2021Review
- Protein adsorption on spark plasma sintered 2d-, 3d- and lamellar type mesoporous silicate compacts.IET nanobiotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New drug delivery system (ZnO@CMS) of the redox and pH dual-stimuli responsive based on colloidal mesoporous silica nanoparticles (CMS) has been designed, in which zinc oxide quantum dots (ZnO QDs) as a capping agent was conjugated on the surface of nanoparticles by amide bonds. The release behaviour of doxorubicin (DOX) as the model drug from ZnO@CMS (ZnO@CMS-DOX) indicated the redox and pH dual-stimuli responsive properties due to the acidic dissolution of ZnO QDs and cleavage of the disulphide bonds. The haemolysis and bovine serum albumin adsorption assays showed that the modification of ZnO QDs on the mesoporous silica nanoparticles modified by mercapto groups (CMS-SH)(ZnO@CMS) had better biocompatibility compared to CMS-SH. The cell viability and cellular uptake tests revealed that the ZnO@CMS might achieve the antitumour effect on cancer cells due to the cytotoxicity of ZnO QDs. Therefore, ZnO@CMS might be potential nanocarriers of the drug delivery system in cancer therapy. The in vivo evaluation of ZnO@CMS would be carried out in future work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.